How should fosfomycin be administered intraperitoneally for peritoneal dialysis-associated peritonitis, including appropriate dosing, duration, and monitoring?

Fosfomycin in Peritoneal Dialysis

Fosfomycin can be administered intraperitoneally at 4 grams per exchange for peritoneal dialysis-associated peritonitis, with demonstrated stability in multiple PD solutions and adequate pharmacokinetic properties, though it should be reserved for culture-directed therapy against susceptible organisms rather than empirical treatment.

Intraperitoneal Administration and Dosing

The recommended dose is 4 grams of fosfomycin administered intraperitoneally 1. This dosing achieves adequate drug concentrations both systemically and intraperitoneally:

• Maximum serum concentrations after intraperitoneal administration reach approximately 206 mg/L 1
• The ratio of intraperitoneal to systemic exposure is 1.12, indicating excellent systemic bioavailability from the peritoneal route 1
• Drug plasma concentrations exceed the minimum inhibitory concentration for susceptible organisms 2

Solution Compatibility and Stability

Fosfomycin demonstrates excellent stability across multiple peritoneal dialysis solutions 3, 4:

• Compatible with Extraneal®, Nutrineal®, Physioneal® 1.36%, and Physioneal® 2.27% 3
• Remains stable for up to 14 days at refrigeration temperature (6°C) or room temperature (25°C) 3
• Stable for 24 hours at body temperature (37°C) 3
• Drug concentrations remain between 94-104% of initial concentrations throughout storage 3
• No significant drug adsorption occurs in any of these solutions 3

This extended stability makes fosfomycin suitable for home-based therapy, as patients can be supplied with pre-mixed bags 3.

Antimicrobial Activity in PD Solutions

The activity of fosfomycin varies depending on the specific PD solution and organism 5:

• Against E. coli: Bactericidal activity demonstrated in Extraneal®, Nutrineal®, and Physioneal® 5
• Against S. aureus and S. epidermidis: Activity maintained but may be reduced compared to standard media 5
• Against P. aeruginosa: Variable activity; resistance can develop (MIC >1024 mg/L in some solutions) 5

The choice of PD solution significantly influences microbiological outcomes in vitro 5.

Special Considerations for Automated Peritoneal Dialysis (APD)

Critical caveat: For patients on APD with peritonitis, pharmacokinetic data suggest that fosfomycin 4 grams IP is likely effective only with dwell times of approximately 15 hours 2.

• With shorter APD dwell times, higher doses may be required 2
• Consider switching patients from APD to continuous ambulatory peritoneal dialysis (CAPD) during peritonitis treatment where pharmacokinetic data are more robust 2

Clinical Role and Indications

Fosfomycin should be used for culture-directed therapy, not empirical treatment 6:

• The 2022 guideline recommends a single 3-gram oral dose for uncomplicated urinary tract infections due to VRE (weak recommendation, very low quality evidence) 6
• For peritoneal dialysis-associated peritonitis, use only after susceptibility testing confirms organism sensitivity
• Particularly useful against multidrug-resistant Enterobacteriaceae, especially E. coli 5

Duration of Treatment

While specific duration data for PD-associated peritonitis are limited in the provided evidence, treatment duration should be:

• Based on clinical response and organism isolated
• Typically aligned with standard peritonitis treatment protocols (14-21 days for most organisms)
• Extended if clinical improvement is delayed

Monitoring Parameters

• Clinical response: Resolution of abdominal pain, clearing of dialysate turbidity
• Dialysate cell counts: Should decrease with effective therapy
• Repeat cultures: If no improvement within 48-72 hours
• Renal function: Though fosfomycin is primarily renally excreted, the half-life increases from 11 to 50 hours in severe renal impairment 7, this is less relevant with intraperitoneal administration

Key Pitfalls to Avoid

1. Do not use fosfomycin empirically - reserve for culture-directed therapy after susceptibility testing
2. Do not assume activity against Pseudomonas - resistance is common and can develop rapidly 5
3. Avoid metoclopramide co-administration - it lowers serum concentrations and urinary excretion of fosfomycin 7
4. Do not use in APD with short dwell times without considering dose adjustment or switching to CAPD 2
5. Verify solution compatibility - while stable in most commercial PD solutions, always confirm the specific product being used 3, 4